| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Akt phosphorylation enhancer; APE; Coiled-coil domain-containing protein 88A; G alpha-interacting vesicle-associated protein; GIV; HkRP1 |
| Entrez GeneID | 55704 |
| WB Predicted band size | Calculated MW: 216 kDa; Observed MW: 216 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant protein of human Girdin |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于GIV抗体的3篇文献示例(内容基于假设性研究，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*GIV Antibody Reveals Its Role in Wnt/β-Catenin Signaling and Colorectal Cancer Metastasis*
**作者**：Smith A, et al.
**摘要**：本研究利用特异性GIV抗体，揭示了GIV蛋白在结直肠癌细胞中通过激活Wnt/β-catenin通路促进肿瘤转移的机制。实验表明，GIV高表达与患者预后不良相关，抗体阻断后可抑制癌细胞侵袭。
---
2. **文献名称**：*Development of a Monoclonal GIV Antibody for Detecting EGFR Signaling Crosstalk in Breast Cancer*
**作者**：Chen L, et al.
**摘要**：作者开发了一种高亲和力GIV单克隆抗体，用于检测乳腺癌组织中GIV与EGFR信号的相互作用。研究发现，GIV通过增强EGFR下游的PI3K-AKT通路驱动肿瘤耐药性，抗体可作为潜在诊断工具。
---
3. **文献名称**：*GIV (CCDC88A) Antibody Identifies Its Prognostic Value in Hepatocellular Carcinoma*
**作者**：Wang Y, et al.
**摘要**：通过免疫组化分析(使用GIV抗体)，本研究证实GIV在肝癌组织中的异常高表达与血管侵袭和复发风险升高相关。机制研究表明，GIV通过调控细胞骨架重组促进转移。
---
如需具体文献，建议在 **PubMed** 或 **Google Scholar** 搜索关键词：
`GIV antibody cancer`、`Girdin/CCDC88A therapeutic target`。
**Background of GIV Antibody**
The GIV antibody targets the Gα-interacting vesicle-associated protein (GIV, also known as Girdin), a multidomain protein implicated in cellular signaling and cytoskeletal regulation. GIV functions as a non-receptor guanine nucleotide exchange factor (GEF) for the Gαi subunit of heterotrimeric G proteins, enabling crosstalk between growth factor receptors (e.g., EGFR, RTKs) and G protein-coupled receptors (GPCRs). This interaction activates downstream pathways, including PI3K-Akt and MAPK, influencing cell migration, proliferation, and survival.
GIV’s role in cancer metastasis and wound healing has drawn significant interest. Overexpression of GIV correlates with poor prognosis in cancers like breast, colorectal, and glioblastoma, where it enhances invasiveness and therapy resistance. Antibodies against GIV are crucial tools for detecting its expression and activation status in tissues or cell lines via techniques like Western blot, immunohistochemistry, or immunofluorescence.
Research-grade GIV antibodies help elucidate its molecular interactions, post-translational modifications (e.g., phosphorylation), and subcellular localization. Therapeutic potential is also explored, as blocking GIV’s GEF activity may inhibit metastatic signaling. However, challenges remain in developing isoform-specific antibodies due to GIV’s structural complexity. Overall, GIV antibodies are pivotal in advancing studies on cellular signaling networks and their pathological dysregulation.
×
